Great good! Anhui requires priority to purchase domestic drugs

Source: Cypress Blue / situ Yangming 2016-08-24 is the best for domestic drugs and domestic medical devices, especially for domestic drugs! As we all know, bidding has the greatest impact on the market of pharmaceutical enterprises, and the most painful thing for domestic pharmaceutical enterprises is that when bidding, foreign drugs occupy the most advantages, with independent quality level, and the bid price is always high Now, that may be over Recently, the general office of the people 's government of Anhui Province issued the notice on printing and distributing the implementation plan for promoting the healthy development of the pharmaceutical industry, which clearly stated that the government procurement of the People's Republic of China should be strictly implemented The general office of the people' s government of Anhui Province issued the notice on printing and distributing the implementation plan for promoting the healthy development of the pharmaceutical industry According to the law, if the domestic drugs and medical devices can meet the requirements, the government procurement projects shall, in principle, purchase domestic products, shall not designate the procurement of imported products, and shall not set specific parameters The drug varieties that pass the consistency evaluation should be properly supported in the aspect of medical insurance payment, and medical institutions should give priority to purchasing and selecting in clinical practice It's a well-known policy orientation to purchase domestic products for devices In addition to devices, Anhui province's policy specifically mentions the priority of purchasing domestic drugs, which is a great advantage for domestic pharmaceutical enterprises It's important to know that only a small amount of drugs in the domestic drug market are patent drugs, and a large number of drugs, especially those in the medical insurance catalog, can Reimbursement and domestic production, this part of the drug market, especially the large hospital market, for foreign expired patent drugs occupy Now, the time for domestic pharmaceutical companies to raise their eyebrows is finally coming With the shortage of medical insurance funds, high-priced drugs, including expired original research drugs, have faced a series of challenges Cypress blue once shared with wechat friends Some local medical insurance departments issued a notice that doctors can only start the country to produce drugs when they prescribe drugs, otherwise they will not be reimbursed There are also price reduction policies for original research drugs For example, in the recently issued trading rules of Guangdong Pharmaceutical exchange, the requirements for expired original research drugs are 10% price reduction range Although the expired original research drugs face great pressure of price reduction, the domestic drugs face greater pressure of price reduction, so the advantages of expired original research drugs are always there However, for domestic pharmaceutical companies, the policy of Anhui Province is definitely a naked advantage, and priority should be given to purchasing It is hoped that the policy will be implemented as soon as possible Only when the domestic medicine is ready for the real good In addition, what else does the document of Anhui Province convey? 1 Support qualified pharmaceutical logistics enterprises to apply for high-tech enterprises To become a high-tech enterprise, there can be a series of advantages in tax and other aspects 2 Do post and express deliver medicine to the grassroots? According to the document, it is necessary to promote large-scale enterprises to build a drug logistics and distribution network throughout urban and rural areas, give full play to the advantages of post and express enterprises in the delivery network, and improve the grass-roots drug supply guarantee capacity Actively develop the third-party logistics 3 Comprehensively promote the two vote system 4 Actively establish the futures market of traditional Chinese medicine 5 Create more than 10 and more than 500 million pharmaceutical varieties and more than 20 and more than 100 million reserve varieties We will strive to create top 10 Wanyao (traditional Chinese medicine produced in Anhui) 6 Welcome to Anhui to build a factory We will provide continuous support to the top 100 multinational pharmaceutical companies in the world, top 50 pharmaceutical companies in China, and newly settled pharmaceutical headquarters or regional and functional headquarters with new investment and actual registered capital of more than 100 million yuan in our province The specific policies will be studied and formulated by the local government For the overall or partial relocation of pharmaceutical production enterprises outside the province to our province or across cities, parallel examination and approval shall be carried out to speed up the handling of drug production license; for the scope of production, registration approval number and GMP certificate of the merged enterprise The following is the original policy of Anhui Province: the general office of the people 's government of Anhui Province issued the implementation plan for promoting the healthy development of the pharmaceutical industry The development of pharmaceutical industry is of great significance to the adjustment and optimization of industrial structure and the protection of people's health The pharmaceutical industry in our province has a certain foundation and maintains a rapid development momentum in recent years, but there are still problems to be solved, such as the small scale of the total amount, the low level of the industry and the weak innovation ability In order to implement the guiding opinions of the general office of the State Council on promoting the healthy development of the pharmaceutical industry (GBF [2016] No 11) and the notice of the national development and Reform Commission on printing and distributing the division plan of key work departments on promoting the healthy development of the pharmaceutical industry (NDRC [2016] No 1523) No.) spirit, accelerate the promotion of the core competitiveness of our province's pharmaceutical industry, and formulate this implementation plan 1 The overall train of thought is to comprehensively implement the spirit of the series of important speeches of the eighteen, eighteen, third, fourth and fifth plenary session of the eighteen Central Committee of the party and general secretary Xi Jinping, firmly establish and earnestly implement the concept of innovation, coordination, green, open and sharing development, grasp the policy opportunities for the reform of the system of examination and approval of drugs and medical devices, and thoroughly implement the "transformation and promotion of 4105" Action plan: adhere to the market-oriented, government led, cluster development and Innovation led, stimulate the innovation and development vitality of the pharmaceutical industry, and strive to achieve the medium and high-speed development of the industry and move towards the medium and high-end level 2、 The main goal is to significantly increase the scale of the pharmaceutical industry by 2020, strive to achieve a main business income of more than 200 billion yuan, with an average annual growth rate of more than 15% The gathering development trend is more prominent, striving to build more than three pharmaceutical industry bases with important influence in the country The innovation capacity has been significantly improved, more than 10 national innovation centers and platforms have been built, a number of major key technologies have been broken through, and a number of new drugs and innovative medical devices have been formed The strength of leading enterprises has been significantly enhanced, and efforts have been made to form more than 10 billion level and more than 20 billion level pharmaceutical enterprise groups The product structure has been significantly optimized, and the structure of APIs and preparations, traditional Chinese medicine and proprietary Chinese medicine has become more reasonable We will create more than 10 large pharmaceutical varieties of 500 million level, 20 large reserve varieties of 100 million level and high-end medical device products with strong competitiveness The brand value has been significantly improved Efforts have been made to cultivate more than 10 well-known brands in the industry, strive to create top 10 Anhui medicine (Anhui produced traditional Chinese Medicine), and sing a green brand The market environment has improved significantly, and the system of government procurement, review and approval to promote the healthy development of the pharmaceutical industry has been gradually established and improved 3、 Key tasks (1) cultivate leading enterprises 1 Strengthen the recruitment and provide continuous support to the top 100 pharmaceutical multinational companies in the world, top 50 pharmaceutical enterprises in China, and newly settled pharmaceutical headquarters or regional and functional headquarters with new investment and actual registered capital of more than 100 million yuan in our province The specific policies shall be studied and formulated by the local government 2 Support the leading enterprises in the province to become bigger and stronger, encourage the strong and strong combination of medicine and chemical industry, medical equipment and equipment, traditional Chinese medicine and proprietary Chinese medicine, API and preparation, production and distribution enterprises, and form an integrated upstream and downstream enterprise group For the relocation of pharmaceutical manufacturing enterprises outside the province or part of them into our province or across cities, parallel examination and approval shall be carried out to speed up the handling of drug production license; for the scope of production, registration approval number and GMP of the merged enterprises ）Certificate, according to the requirements of relevant laws and regulations, shall be changed to the pharmaceutical manufacturing enterprise after merger and reorganization We will support enterprises to speed up their competitiveness by purchasing approval documents for clinical trials of new drugs and transferring production technologies 3 Take the leading enterprises as the main body, and work with relevant enterprises and scientific research institutes to establish provincial chemical medicine, proprietary Chinese medicine, biopharmaceutical, medical equipment and other industrial alliances, so as to give full play to the role of industrial alliances in collaborative innovation and demonstration application Around the supporting of leading enterprises, we will develop a number of small and medium-sized enterprises, such as pharmaceutical intermediates, excipients and packaging materials, with high technology and quality, and form an industrial organization structure of division of labor and cooperation, mutual benefit and win-win results for large and medium-sized enterprises Relying on the provincial excellent enterprise pool of strategic emerging industries, select excellent pharmaceutical enterprises, and focus on factor resources to support, so as to accelerate the growth of enterprises (responsible unit: led by the relevant municipal people's government and the provincial development and Reform Commission, with the cooperation of the Provincial Department of science and technology, the provincial economic and Information Commission, the Provincial Department of Commerce, the provincial food and drug administration, etc.) (II) construction of industrial base 1 Accelerate the construction of Fuyang Taihe modern medicine industry cluster development base, vigorously develop chemical pharmacy, biological medicine and modern Chinese medicine, improve the development level of preparations, and build an important national modern medicine industry base 2 Speed up the construction of Bozhou modern Chinese medicine industry cluster development base, carry out large-scale and standardized planting (breeding) of Chinese medicine, improve the development level of Chinese medicine pieces and extracts, develop Chinese patent medicine and Chinese medicine health care, Chinese medicine daily chemical series products, and build an important national modern Chinese medicine industry base 3 Give full play to the basic advantages of science and education, talents and industry in Hefei, focus on biomedicine, biomedical engineering, precision medicine and other fields, promote the development of digital diagnosis and treatment equipment, high-end medical imaging equipment, medical biomaterials and other industries, cultivate professional services such as gene sequencing and cell therapy, and build an important life and health industry base in China 4 Encourage qualified cities to build municipal pharmaceutical industrial bases in combination with the actual situation, and timely identify those that meet the conditions as provincial pharmaceutical industrial bases We will support provincial pharmaceutical industry bases to apply for the construction of national pharmaceutical industry bases (responsible unit: led by the relevant municipal people's government and the provincial development and Reform Commission, coordinated by the Provincial Department of science and technology, the provincial economic and Information Commission, the Provincial Department of finance, the provincial food and drug administration, the provincial investment group, the provincial credit guarantee group, etc.) (3) improve the innovation ability 1 Strengthen the construction of innovation capacity in the fields of original research drugs, first generic drugs, traditional Chinese medicine, new preparations, high-end medical devices, etc., and build public service platforms such as technology research and development, industrialization, safety evaluation, clinical evaluation of pharmaceutical products, relying on leading enterprises, colleges and medical institutions by using database, computer screening, Internet and other information technologies In view of major diseases such as malignant tumors, cardio cerebrovascular diseases and sudden infectious diseases, we will promote the innovation and application of cutting-edge technologies such as high-throughput gene sequencing and molecular immunity 2 Actively strive for the layout of national pharmaceutical innovation center and innovation platform in our province Strengthen the capacity building of Anhui medical device testing center and improve the testing level Accelerate the construction of Hefei ion medical center, tumor medical center and regional cell preparation center, and support Hefei to build a first-class professional incubator of biomedicine in China We will encourage qualified tertiary grade A hospitals in the province to build phase I clinical bases and other platforms In Fuyang Taihe, Bozhou and other provincial pharmaceutical industry bases and qualified regions, we will build public service platforms such as research and development of key generic technologies, inspection and testing, and high-level pharmaceutical industry innovation centers 3 For the small-scale and pilot production lines of APIs that meet the needs of new drug development and regulatory requirements, it is allowed to build in the existing workshops with safety assurance, and through strengthening